[Ibuprofen in rheumatic, degenerative and traumatic disorders of the locomotor system. Local effects and tolerance].
The clinical trials carried out on Dolgit Creme containing 5% of the nonsteroidal antirheumatic active principle ibuprofen were carried out by 12 clinical examiners. The experimental and clinical tests were carried out on a total of 464 patients and/or volunteers. It has been proved that the active principle ibuprofen of the tested creme penetrates throughout the skin without causing serum concentrations which could lead to the appearance of undesirable side effects. The metabolization of ibuprofen after topical administration coincides with that following oral administration. In comparative studies with nonsteroidal antirheumatic gel it has been possible to prove the efficacy of Dolgit Creme in the treatment of the different forms of rheumatic diseases and degenerative articular changes as well as in cases of accident and sports injuries. The efficacy of Dolgit Creme compared to Placebo in a double blind trial for the assessment of the onset of action, pain alleviation, decrease of swelling, improvement of motility was at the 1%-level significantly superior. The effective dosage assessed was three or more times daily to apply a 4-10 cm strip of the creme on the affected part of the tissue and massage. Undesirable side effects appeared in less than 4% of the cases in the form of allergic skin reactions.
D000287:Administration, Topical; D001265:Athletic Injuries / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004361:Drug Tolerance; D006801:Humans; D007052:Ibuprofen / Q000008:administration & dosage*; D010919:Placebos; D012216:Rheumatic Diseases / Q000188:drug therapy*
D010919:Placebos; D007052:Ibuprofen
Ibuprofen bei rheumatischen, degenerativen und traumatischen Erkrankungen des Bewegungsapprats. Zur lokalen Wirksamkeit und Verträglichkeit.